NASDAQ:CDNA - CareDx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.82 +0.12 (+1.03 %)
(As of 05/25/2018 03:33 AM ET)
Previous Close$11.82
Today's Range$11.57 - $11.94
52-Week Range$0.95 - $11.99
Volume233,674 shs
Average Volume336,192 shs
Market Capitalization$416.34 million
P/E Ratio-15.35
Dividend YieldN/A
Beta0.34

About CareDx (NASDAQ:CDNA)

CareDx logoCareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300

Debt

Debt-to-Equity Ratio0.29
Current Ratio2.43
Quick Ratio2.06

Price-To-Earnings

Trailing P/E Ratio-15.35
Forward P/E Ratio-24.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$48.32 million
Price / Sales8.63
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book12.44

Profitability

EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-115.91%
Return on Equity-158.93%
Return on Assets-19.78%

Miscellaneous

Employees179
Outstanding Shares35,280,000

CareDx (NASDAQ:CDNA) Frequently Asked Questions

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) released its earnings results on Thursday, May, 10th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The firm earned $14.05 million during the quarter, compared to analyst estimates of $13.91 million. CareDx had a negative net margin of 115.91% and a negative return on equity of 158.93%. View CareDx's Earnings History.

What price target have analysts set for CDNA?

4 brokers have issued 12 month target prices for CareDx's stock. Their predictions range from $6.50 to $14.00. On average, they expect CareDx's stock price to reach $9.3750 in the next year. View Analyst Ratings for CareDx.

Who are some of CareDx's key competitors?

Who are CareDx's key executives?

CareDx's management team includes the folowing people:
  • Dr. Peter Maag, Pres, CEO & Director (Age 51)
  • Mr. Michael Bell, Chief Financial Officer (Age 49)
  • Dr. James P. Yee, Chief Medical Officer (Age 69)
  • Dr. Mitchell J. Nelles, Chief Operating Officer (Age 65)
  • Dr. John J. Sninsky Ph.D., Chief Scientific Officer (Age 68)

Has CareDx been receiving favorable news coverage?

Media coverage about CDNA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a coverage optimism score of 0.04 on Accern's scale. They also assigned press coverage about the company an impact score of 46.55 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are CareDx's major shareholders?

CareDx's stock is owned by many different of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (5.08%), MIDROC INVEST AB (4.50%), Next Century Growth Investors LLC (4.47%), Polar Asset Management Partners Inc. (2.44%), Park West Asset Management LLC (1.41%) and Millrace Asset Group Inc. (0.85%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.

Which major investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Thompson Davis & CO. Inc. and Gagnon Securities LLC. Company insiders that have sold CareDx company stock in the last year include James P Yee, Mitchell J Nelles and Peter Maag. View Insider Buying and Selling for CareDx.

Which major investors are buying CareDx stock?

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Next Century Growth Investors LLC, Millrace Asset Group Inc., Millennium Management LLC, Spark Investment Management LLC, Trexquant Investment LP, Tibra Equities Europe Ltd and Clear Harbor Asset Management LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $11.82.

How big of a company is CareDx?

CareDx has a market capitalization of $416.34 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.

How can I contact CareDx?

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]


MarketBeat Community Rating for CareDx (CDNA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CareDx (NASDAQ:CDNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for CareDx in the last 12 months. Their average twelve-month price target is $9.3750, suggesting that the stock has a possible downside of 20.69%. The high price target for CDNA is $14.00 and the low price target for CDNA is $6.50. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.3750$8.8750$8.8750$7.8333
Price Target Upside: 20.69% downside2.96% upside45.25% upside39.38% upside

CareDx (NASDAQ:CDNA) Consensus Price Target History

Price Target History for CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018HC WainwrightReiterated RatingBuy$14.00MediumView Rating Details
10/9/2017Craig HallumReiterated RatingBuy$4.00 ➝ $10.00N/AView Rating Details
9/27/2017Raymond JamesUpgradeMarket Perform ➝ Buy$6.50HighView Rating Details
9/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$3.00 ➝ $7.00HighView Rating Details
6/14/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/14/2016MizuhoBoost Price TargetBuy$8.00 ➝ $12.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

CareDx (NASDAQ:CDNA) Earnings History and Estimates Chart

Earnings by Quarter for CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.08)($0.08)($0.08)

CareDx (NASDAQ CDNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.13)($0.14)$13.91 million$14.05 millionViewListenView Earnings Details
3/22/2018Q4 2017($0.1450)($0.09)$12.09 million$12.50 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.17)($0.15)$12.05 million$12.19 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.19)($0.19)$11.87 million$12.05 millionViewN/AView Earnings Details
6/9/2017Q1 2017($0.27)($0.34)$11.23 million$11.58 millionViewN/AView Earnings Details
4/21/2017Q4 2016($0.15)$10.77 million$10.86 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.25)($0.17)$11.50 million$12.48 millionViewListenView Earnings Details
8/10/2016Q216($0.28)($0.29)$10.42 million$10.70 millionViewListenView Earnings Details
5/6/2016Q1($0.31)($0.37)$6.97 million$6.60 millionViewN/AView Earnings Details
3/24/2016Q415($0.34)($0.40)$7.44 million$6.60 millionViewListenView Earnings Details
11/11/2015Q315($0.25)($0.29)$7.34 million$7.15 millionViewListenView Earnings Details
8/10/2015Q215($0.18)($0.27)$7.28 million$7.13 millionViewListenView Earnings Details
5/12/2015Q115($0.17)($0.19)$6.82 million$7.22 millionViewListenView Earnings Details
11/10/2014Q314($0.13)$0.01$6.60 million$6.65 millionViewN/AView Earnings Details
8/27/2014Q2 14($0.13)($0.09)$6.18 million$6.78 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CareDx (NASDAQ:CDNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CareDx (NASDAQ CDNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.40%
Institutional Ownership Percentage: 51.87%
Insider Trading History for CareDx (NASDAQ:CDNA)
Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

CareDx (NASDAQ CDNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/26/2018Neil GagnonMajor ShareholderBuy10,136$9.42$95,481.12928,768View SEC Filing  
3/27/2018Peter MaagInsiderSell15,000$7.87$118,050.00272,037View SEC Filing  
12/8/2017James P YeeInsiderSell29,197$7.00$204,379.0074,795View SEC Filing  
11/30/2017Mitchell J NellesCOOSell10,948$7.17$78,497.1684,225View SEC Filing  
10/5/2017Neil GagnonMajor ShareholderBuy10,642$4.00$42,568.00View SEC Filing  
9/7/2017Neil GagnonMajor ShareholderBuy6,496$3.05$19,812.80916,546View SEC Filing  
8/28/2017Neil GagnonMajor ShareholderBuy21,448$2.77$59,410.96903,731View SEC Filing  
8/25/2017Neil GagnonMajor ShareholderBuy35,119$2.92$102,547.48890,473View SEC Filing  
8/15/2017Michael Brian BellCFOBuy725$1.83$1,326.75375View SEC Filing  
8/15/2017Peter MaagInsiderBuy600$1.82$1,092.00107,350View SEC Filing  
7/24/2017Neil GagnonMajor ShareholderBuy1,486$1.23$1,827.78886,216View SEC Filing  
6/29/2017Neil GagnonMajor ShareholderBuy1,808$1.11$2,006.88886,216View SEC Filing  
6/23/2017Neil GagnonMajor ShareholderBuy63,120$1.10$69,432.00886,216View SEC Filing  
5/24/2017Neil GagnonMajor ShareholderBuy7,439$1.00$7,439.00879,914View SEC Filing  
5/23/2017Neil GagnonMajor ShareholderBuy6,836$1.04$7,109.44878,777View SEC Filing  
4/28/2017Neil GagnonMajor ShareholderBuy15,116$0.89$13,453.24873,928View SEC Filing  
3/16/2017Neil GagnonMajor ShareholderBuy123,160$1.83$225,382.80778,133View SEC Filing  
9/22/2016Neil GagnonMajor ShareholderBuy178,686$4.00$714,744.00613,473View SEC Filing  
4/14/2016Neil GagnonMajor ShareholderBuy93,240$4.02$374,824.80419,638View SEC Filing  
10/21/2015Neil Gagnonmajor shareholderBuy1,431$4.99$7,140.691,243,852View SEC Filing  
10/20/2015Neil GagnonMajor ShareholderBuy1,347$4.92$6,627.241,242,421View SEC Filing  
9/29/2015Neil Gagnonmajor shareholderBuy6,332$6.10$38,625.201,240,886View SEC Filing  
9/4/2015Neil GagnonMajor ShareholderBuy69,383$6.95$482,211.85View SEC Filing  
6/5/2015Neil GagnonMajor ShareholderBuy6,500$5.69$36,985.00View SEC Filing  
6/1/2015Peter MaagCEOBuy2,000$4.84$9,680.00View SEC Filing  
4/17/2015Neil GagnonMajor ShareholderBuy13,051$5.34$69,692.34View SEC Filing  
3/20/2015Neil GagnonMajor ShareholderBuy6,324$6.35$40,157.40View SEC Filing  
2/27/2015Neil GagnonMajor ShareholderBuy4,270$6.03$25,748.10View SEC Filing  
2/6/2015Neil GagnonMajor ShareholderBuy4,586$7.20$33,019.20View SEC Filing  
2/5/2015Neil GagnonMajor ShareholderBuy121,587$7.10$863,267.70View SEC Filing  
2/4/2015Neil GagnonMajor ShareholderBuy31,991$7.00$223,937.00View SEC Filing  
2/3/2015Neil GagnonMajor ShareholderBuy23,558$7.03$165,612.74View SEC Filing  
2/2/2015Neil GagnonMajor ShareholderBuy3,620$7.05$25,521.00View SEC Filing  
1/29/2015Neil GagnonMajor ShareholderBuy15,395$7.04$108,380.80View SEC Filing  
1/27/2015Neil GagnonMajor ShareholderBuy84,720$7.00$593,040.00View SEC Filing  
1/22/2015Neil GagnonMajor ShareholderBuy48,670$7.13$347,017.10View SEC Filing  
1/20/2015Neil GagnonMajor ShareholderBuy16,192$6.66$107,838.72View SEC Filing  
1/15/2015Neil GagnonMajor ShareholderBuy39,109$6.43$251,470.87View SEC Filing  
1/14/2015Neil GagnonMajor ShareholderBuy122,319$7.07$864,795.33View SEC Filing  
7/22/2014Ken LudlumCFOBuy7,000$10.00$70,000.00View SEC Filing  
7/22/2014Michael GoldbergDirectorBuy25,000$10.00$250,000.00View SEC Filing  
7/22/2014Perkins Caufield & Bye KleinerMajor ShareholderBuy52,770$10.00$527,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CareDx (NASDAQ CDNA) News Headlines

Source:
DateHeadline
CareDx to Hold Press Conference at American Transplant CongressCareDx to Hold Press Conference at American Transplant Congress
finance.yahoo.com - May 24 at 9:47 AM
Zacks: Brokerages Expect CareDx (CDNA) Will Post Quarterly Sales of $15.35 MillionZacks: Brokerages Expect CareDx (CDNA) Will Post Quarterly Sales of $15.35 Million
www.americanbankingnews.com - May 22 at 5:23 AM
CareDx (CDNA) Receives Consensus Recommendation of "Buy" from BrokeragesCareDx (CDNA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 21 at 7:52 AM
Zacks: Brokerages Expect CareDx (CDNA) Will Post Earnings of -$0.05 Per ShareZacks: Brokerages Expect CareDx (CDNA) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - May 20 at 1:16 AM
CareDx (CDNA) Lowered to Buy at BidaskClubCareDx (CDNA) Lowered to Buy at BidaskClub
www.americanbankingnews.com - May 15 at 10:33 AM
CareDxs (CDNA) CEO Peter Maag on Q1 2018 Results - Earnings Call TranscriptCareDx's (CDNA) CEO Peter Maag on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 4:58 PM
CareDx (CDNA) Earns Buy Rating from HC WainwrightCareDx (CDNA) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - May 11 at 7:49 PM
CareDx (CDNA) Releases Quarterly  Earnings Results, Misses Estimates By $0.01 EPSCareDx (CDNA) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 11 at 5:41 PM
CareDx, Inc (CDNA)CareDx, Inc (CDNA)
finance.yahoo.com - May 11 at 4:19 PM
CareDx down 1.8% post Q1 resultsCareDx down 1.8% post Q1 results
seekingalpha.com - May 11 at 12:28 PM
CareDx: 1Q Earnings SnapshotCareDx: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 10:41 AM
Edited Transcript of CDNA earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of CDNA earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:41 AM
CareDx misses by $0.01, beats on revenueCareDx misses by $0.01, beats on revenue
seekingalpha.com - May 10 at 4:25 PM
CareDx Reports First Quarter ResultsCareDx Reports First Quarter Results
finance.yahoo.com - May 10 at 4:25 PM
BRIEF-Caredx Inc Enters Into A License And Commercialization Agreement With IlluminaBRIEF-Caredx Inc Enters Into A License And Commercialization Agreement With Illumina
www.reuters.com - May 9 at 9:41 AM
CareDx expands NGS Transplant Product OfferingsCareDx expands NGS Transplant Product Offerings
finance.yahoo.com - May 9 at 9:41 AM
CareDx (CDNA) Upgraded to "Strong-Buy" by BidaskClubCareDx (CDNA) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - May 5 at 1:03 AM
CareDx (CDNA) Expected to Post Quarterly Sales of $13.91 MillionCareDx (CDNA) Expected to Post Quarterly Sales of $13.91 Million
www.americanbankingnews.com - May 4 at 3:02 AM
CareDx (CDNA) Upgraded to Strong-Buy at ValuEngineCareDx (CDNA) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 3 at 10:18 PM
CareDx (CDNA) Scheduled to Post Quarterly Earnings on ThursdayCareDx (CDNA) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 2:36 AM
CareDx Activities at American Transplant CongressCareDx Activities at American Transplant Congress
finance.yahoo.com - May 1 at 9:38 AM
Insider Buying: CareDx (CDNA) Major Shareholder Purchases 10,136 Shares of StockInsider Buying: CareDx (CDNA) Major Shareholder Purchases 10,136 Shares of Stock
www.americanbankingnews.com - April 30 at 8:02 PM
Critical Contrast: CareDx (CDNA) vs. Biocept (BIOC)Critical Contrast: CareDx (CDNA) vs. Biocept (BIOC)
www.americanbankingnews.com - April 29 at 5:20 AM
Financial Contrast: CareDx (CDNA) vs. Its CompetitorsFinancial Contrast: CareDx (CDNA) vs. Its Competitors
www.americanbankingnews.com - April 29 at 3:08 AM
Analyzing CareDx (CDNA) and Its PeersAnalyzing CareDx (CDNA) and Its Peers
www.americanbankingnews.com - April 27 at 3:18 PM
Free Post Earnings Research Report: CareDx’s Quarterly Sales Rose 15%; Adjusted Net Loss NarrowedFree Post Earnings Research Report: CareDx’s Quarterly Sales Rose 15%; Adjusted Net Loss Narrowed
finance.yahoo.com - April 25 at 9:47 AM
Factors of Influence in 2018, Key Indicators and Opportunity within LATAM ...Factors of Influence in 2018, Key Indicators and Opportunity within LATAM ...
globenewswire.com - April 24 at 9:37 AM
Head to Head Comparison: CareDx (CDNA) versus The CompetitionHead to Head Comparison: CareDx (CDNA) versus The Competition
www.americanbankingnews.com - April 22 at 3:16 PM
CareDx (CDNA) Rating Increased to Buy at BidaskClubCareDx (CDNA) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 20 at 11:39 AM
Head to Head Contrast: CareDx (CDNA) versus Its PeersHead to Head Contrast: CareDx (CDNA) versus Its Peers
www.americanbankingnews.com - April 20 at 11:08 AM
BRIEF-Caredx Enters Into A Credit Agreement And Guaranty - SEC FilingBRIEF-Caredx Enters Into A Credit Agreement And Guaranty - SEC Filing
www.reuters.com - April 18 at 9:40 AM
CareDx Closes Debt RefinancingCareDx Closes Debt Refinancing
finance.yahoo.com - April 18 at 9:40 AM
CareDx (CDNA) versus Its Rivals Critical SurveyCareDx (CDNA) versus Its Rivals Critical Survey
www.americanbankingnews.com - April 17 at 7:19 PM
$13.86 Million in Sales Expected for CareDx (CDNA) This Quarter$13.86 Million in Sales Expected for CareDx (CDNA) This Quarter
www.americanbankingnews.com - April 17 at 3:29 AM
Financial Analysis: CareDx (CDNA) and Its CompetitorsFinancial Analysis: CareDx (CDNA) and Its Competitors
www.americanbankingnews.com - April 17 at 3:13 AM
CareDx (CDNA) Rating Lowered to Hold at Zacks Investment ResearchCareDx (CDNA) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:16 PM
Critical Contrast: CareDx (CDNA) & Its CompetitorsCritical Contrast: CareDx (CDNA) & Its Competitors
www.americanbankingnews.com - April 15 at 5:15 PM
CareDx (CDNA) Expected to Post Earnings of -$0.12 Per ShareCareDx (CDNA) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - April 15 at 1:23 PM
CareDx (CDNA) vs. Its Competitors Critical ReviewCareDx (CDNA) vs. Its Competitors Critical Review
www.americanbankingnews.com - April 13 at 5:21 PM
Financial Contrast: CareDx (CDNA) & Its PeersFinancial Contrast: CareDx (CDNA) & Its Peers
www.americanbankingnews.com - April 13 at 11:51 AM
Olerup QTYPE® Receives CE Mark CertificationOlerup QTYPE® Receives CE Mark Certification
finance.yahoo.com - April 13 at 10:07 AM
CareDx (CDNA) Sees Significant Drop in Short InterestCareDx (CDNA) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 13 at 2:10 AM
CareDx (CDNA) Stock Rating Reaffirmed by HC WainwrightCareDx (CDNA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 12 at 10:45 AM
CareDx (CDNA) Upgraded to C- at TheStreetCareDx (CDNA) Upgraded to C- at TheStreet
www.americanbankingnews.com - April 12 at 10:19 AM
CareDx launches rejection surveillance solution for heart transplant recipientsCareDx launches rejection surveillance solution for heart transplant recipients
seekingalpha.com - April 10 at 4:18 PM
Analyzing CareDx (CDNA) & Its PeersAnalyzing CareDx (CDNA) & Its Peers
www.americanbankingnews.com - April 10 at 11:18 AM
BRIEF-Caredx Launches Heartcare For Heart Transplant RecipientsBRIEF-Caredx Launches Heartcare For Heart Transplant Recipients
www.reuters.com - April 10 at 10:05 AM
CareDx Launches HeartCare® for Heart Transplant RecipientsCareDx Launches HeartCare® for Heart Transplant Recipients
finance.yahoo.com - April 10 at 10:05 AM
CareDx (CDNA) and Its Peers Critical ComparisonCareDx (CDNA) and Its Peers Critical Comparison
www.americanbankingnews.com - April 8 at 3:13 PM
Critical Comparison: CareDx (CDNA) versus Biocept (BIOC)Critical Comparison: CareDx (CDNA) versus Biocept (BIOC)
www.americanbankingnews.com - April 5 at 3:08 AM

SEC Filings

CareDx (NASDAQ:CDNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CareDx (NASDAQ:CDNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CareDx (NASDAQ CDNA) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.